Vigil Neuroscience Reports Positive Phase 1 Data for VG-3927 in Alzheimer’s Disease Treatment

January 23, 2025

DENVER, Colo., Jan 23, 2025 (247marketnews.com)- Vigil Neuroscience (NASDAQ: VIGL) reported positive Phase 1 results from its VG-3927 trial. The trial evaluated VG-3927 for the potential treatment of Alzheimer’s Disease. The trial’s results support advancing VG-3927 into a Phase 2 trial as a once-daily oral treatment for AD.

Ivana Magovčević-Liebisch, Ph.D., J.D., President and CEO of Vigil Neuroscience, stated, “We are thrilled by these promising Phase 1 results, which reinforce the potential of VG-3927 as a next-generation therapy for AD. As the first Phase 2-ready oral TREM2 agonist, VG-3927 provides a unique profile that goes beyond targeting amyloid plaques. It has the potential to address other contributors to disease progression while offering a more convenient treatment option for those suffering from AD.”

The Phase 1 trial included 115 participants and assessed the safety, tolerability, PK, and PD of VG-3927 across 14 cohorts. The trial evaluated 8 single ascending dose cohorts and 4 multiple ascending dose cohorts.

VG-3927 showed a favorable safety profile, with all adverse events mild or moderate and self-resolving, with no drug discontinuations or serious adverse events reported. VG-3927 demonstrated excellent brain penetration and a predictable PK profile, supporting its potential as a once-daily oral treatment. The drug achieved a robust and dose-dependent reduction of sTREM2 in cerebral spinal fluid, showing strong PK/PD relationships, sustained target engagement, and TREM2 agonist activity.

Petra Kaufmann, M.D., F.A.A.N., Vigil’s CMO, commented, “We are excited to report that VG-3927 is Phase 2-ready. The favorable safety profile, coupled with strong target engagement and neuroprotective potential, makes VG-3927 a promising candidate for AD treatment. We look forward to advancing our clinical program to bring a new therapy to patients with this challenging disease.”

Vigil plans to present additional data from the trial at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VIGL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.